Topical or injected: two different offers under one name
A serum applied after microneedling and an injection into the scalp or dermis are described with the same vocabulary and are not the same proposition. How they differ in delivery, in regulatory position and in what you are being asked to accept.
Published by Valextino Ltd. Published 2026-09-01. Last reviewed 2026-09-01. Information only. This site is not a clinic and gives no medical advice.
Two quite different things are sold under the same name. In one, a preparation is applied to the skin surface, usually immediately after microneedling or another treatment that has opened channels in the skin. In the other, a preparation is injected into the scalp or the dermis. The delivery route changes what reaches the target, what the risks are, and what regulatory questions apply.
Whichever is offered, the question to settle first is what is actually in the syringe or the vial, who made it, and what its regulatory status in the UK is. That question sits ahead of the route, because a route is a detail of administration and the status of the material is not.
Why the two get blurred
Marketing language for this category describes an outcome rather than a procedure. Regenerative, cell free, signalling, restorative: none of those words tells you whether anything is going to be injected. It is common to read a clinic page from beginning to end and still not know which of the two is being offered, and it is common for the answer to be settled in the room.
The blur is not always deliberate. The same trade name is often used for a product supplied in a form that can be applied topically and a form intended for injection, and clinics that offer both describe them together. But a reader deciding whether to book has been given one price and one word for two different propositions, and the differences are not cosmetic.
Delivery: what the route actually changes
Skin is a barrier, and it is very good at its job. Large molecules and particles do not cross intact stratum corneum in useful quantities, which is the reason topical delivery of anything large is difficult and the reason microneedling is paired with these preparations at all. The channels created by needling are transient, and how much passes through them depends on the depth, the density of channels, the size of what is being applied and how quickly the channels close.
Injection bypasses the barrier entirely and places material at a chosen depth. That is a real difference in delivery, and it is also a real difference in risk, because everything that was outside the body is now inside it. The consequences of a contaminated or mischaracterised preparation are not comparable between the two routes.
| Applied to the skin after needling | Injected | |
|---|---|---|
| How the barrier is crossed | Through transient channels made by needles | Bypassed entirely, at a depth the operator selects |
| How much reaches the target | Depends on channel depth and density, particle size and how fast the channels close | Placed directly, though distribution afterwards is still not controlled |
| Main risks | Those of the needling itself, plus reaction to what is applied to opened skin | Those of any injection, including infection, plus reaction to the material |
| What the paired treatment contributes | Substantial, and difficult to separate from the preparation | Variable, since injection may be given alone |
| Regulatory questions raised | Depends on how the product is classified and what is claimed | Broader, because a biological material is being introduced into the body |
The regulatory question is not the same for the two
This is the part most worth understanding before a price is discussed. Products intended to be injected sit in a different regulatory world from products applied to the surface of the skin, and biological material derived from human cells raises questions that a cosmetic ingredient does not.
The bodies whose remit can be engaged are the Medicines and Healthcare products Regulatory Agency, which regulates medicines and medical devices and decides how a product is classified, the Human Tissue Authority, whose remit covers human tissue and cells for certain purposes, the Care Quality Commission, which regulates certain healthcare providers in England, and the Advertising Standards Authority, which polices whether a claim can be substantiated. Which of them applies depends on what the product is, what it is made from and what is claimed for it, which is exactly why the composition question comes before everything else.
Regulatory positions in this area have moved and can move again. Rather than repeating a status here that may be out of date by the time you read it, the reliable move is to ask the clinic for the product name and the manufacturer, then check the current position with the MHRA directly. A product that cannot be named is a product whose status cannot be checked, and that is the answer to the question.
| Establish | Why it matters |
|---|---|
| Whether anything is injected | It is the single biggest difference and it is often not stated |
| The product name and the manufacturer, in writing | A product that cannot be named cannot be checked with a regulator |
| What the material is derived from | Human derived material engages a different regulatory picture from a synthetic one |
| What the paired treatment is, and its standalone price | It separates what you are paying for the preparation from what you are paying for needling |
| Who is administering it, and their registration | Injecting is a clinical act, and the person doing it should be registered and named |
| What happens if there is a reaction, and who you call | A plan agreed in advance is worth more than reassurance given in the chair |
What the paired treatment is doing
Where a preparation is applied after microneedling, radiofrequency microneedling or a laser, part of what you are paying for is the paired treatment, and that part has its own evidence and its own effect. Microneedling produces a repair response by itself. So does radiofrequency microneedling, which Morpheus8 Elite covers in the detail this site does not.
The practical consequence is that an improvement after a combined treatment cannot be attributed to the applied preparation, because the needling alone would be expected to produce something. Any claim that separates the two has to come from a study that separated them, which returns you to the design question.
It also has a pricing consequence worth naming. If the paired treatment is priced separately elsewhere, the difference between the two prices is what is being charged for the preparation, and that is a number you can work out and think about.
How to hold the conversation
You are not choosing between two techniques on their merits. You are establishing what is being offered, then deciding whether the answer is good enough. Four things settle it.
First, ask directly whether anything will be injected. Second, ask for the product name and the manufacturer, in writing, before the appointment rather than in the chair. Third, ask what the paired treatment is and what it costs on its own. Fourth, ask what the plan is if there is a reaction, and who you contact out of hours. A provider who answers all four plainly has told you what you needed to know, whichever route they use.
What this page does not cover
This page compares delivery routes and the questions each raises. It does not tell you what any specific product is, what it contains or what its current regulatory status is, because that changes and because it depends on the product. It names no product, manufacturer, clinic or price. It does not cover the biology, sourcing, isolation or characterisation of extracellular vesicles, which belong to Exosomal Therapy. It is a general reference and not medical advice, and it cannot substitute for assessment by a clinician who can examine you and take a history.
Common questions
Is a topical exosome serum the same treatment as an injection
No. The delivery route changes what reaches the target, what the risks are and which regulatory questions apply. They are commonly described in the same language and priced as one offer, which is why it is worth asking directly whether anything will be injected.
Are exosome injections legal in the UK
The position depends on what the product is, what it is made from and what is claimed for it, and it has moved over time. Ask the clinic for the product name and the manufacturer, then check the current position with the MHRA rather than relying on a page like this one to be current.
Does anything actually get through the skin after microneedling
Channels made by needling are transient and how much passes through them depends on their depth and density, on the size of what is applied and on how quickly they close. That is a reason to ask what the evidence is for the specific combination being offered, rather than for either part alone.
How do I know what I am being charged for
Ask the price of the paired treatment on its own. The difference between that and the combined price is what is being charged for the preparation, which is a number worth seeing before you decide.
Who should be administering an injection
A registered clinician, named, with a clear route to reach them afterwards. Ask who it will be and on which register they appear before the appointment rather than on the day.
What should I ask to have in writing
The product name and manufacturer, what is derived from what, who is administering it, and what happens if there is a reaction. A provider comfortable with the offer will put those in an email.
This page contains no commercial links of any kind. No clinic, practitioner, product or supplier is named, recommended or linked to, and nobody has paid for, influenced or previewed anything on it. External links go only to UK regulators and professional bodies and carry a nofollow attribute. Published by Valextino Ltd under our editorial policy.